TRI Grant Schemes

TRI launched a formal Research Grant Program in 2015 to support translational research projects based at the institute. Between 2015-2019, two grant schemes were available: Spore and Drive. Through these schemes, TRI awarded $850,000 via 13 grants, with TRI’s partner institutions and industry collaborators matched this funding with a further $1,571,745. TRI is currently reviewing its Grant Program to ensure it maximises the translational support available to researchers based at the institute.

Spore Grants were awarded to support multidisciplinary teams of scientists and clinicians from a combination of academic, commercial and clinical backgrounds to test innovative ideas. The scheme provided funding of up to $90,000 per grant for 12 months, including matched funding from our partner institutions. TRI awarded 12 Spore Grants, with the scheme offered in 2015, 2016, 2018 and 2019. 

Drive Grants aimed to accelerate translation of innovations into the clinic, bringing together multidisciplinary teams of scientists, clinicians and commercial partners to address an unmet clinical need. This scheme supported research projects that are beyond proof-of-concept stage, address an important clinical question, and have a defined translational outcome. Areas of interest can include, but are not limited to, research addressing new therapeutics, diagnostics, medical devices, digital health, new clinical intervention programs and repurposing of new drugs. The scheme provided funding of up to $500,000 per grant over three years. 

TRI research grant recipients

Year awarded

Grant scheme

Principal Investigator

Project title

2015

Spore

Dr Michelle Hill

Obesity-induced Barrett’s oesophagus and associated cancer: mechanisms and diagnostic tools

2015

Spore

Dr Antje Blumenthal

Towards biomarkers for patient stratification in sepsis

2015

Spore

Prof Rik Thompson

Portable, single-sided MRI for routine, low-cost analysis of mammographic density

2015

Spore

Prof Ken O'Byrne

Nucleoplasmin (NPM)1 a critical repair protein required for genomic stability

2016

Spore

A/Prof Jyotsna Batra

Novel MicroRNA’s as potential targets for treating prostate cancer

2016

Spore

A/Prof Chamindie Punyadeera

Circulating Tumour Cells as Biomarkers to Identify Head and Neck Cancer Patients for PD1 Therapy

2018

Spore

Prof Gerald Holtmann

Modulation of the GI Microbiome with probiotics to treat constipation

2018

Spore

Prof John Hooper

Theranostic biomolecules for improved diagnosis and treatment of pancreatic cancer

2018

Spore

Dr Arutha Kulasinghe

Can liquid biopsy provide predictive biomarkers for checkpoint inhibitor response in Non-Small Cell Lung Cancer?

2018

Spore

Prof Peter Soyer

Towards clinical diagnosis of inflammatory skin rashes using minimally‐invasive micro-sampling technologies

2019

Spore

A/Prof Jyotsna Batra

Improving the PSA test to detect all lethal prostate cancers

2019

Spore

Prof Ben Panizza

Therapeutic Potential for the Treatment of Adenoid Cystic Carcinoma (ACC)

2019

Drive

Prof Sandro Porceddu

Durvax Trial: A Phase 1b, single centre, open label study of a therapeutic Human Papilomavirus (HPC) DNA vaccine co-administered with anti-PD-L1 immunotheraphy, Duravalumab (MED14736), for recurrent and/or metastatic HPV-related oropharnygeal cancer